期刊文献+

血浆外泌体miR-423-5p在前列腺癌骨转移患者中的差异表达分析 被引量:5

Analysis of differential expression of plasma exosome miR-423-5p in patients with prostate cancer bone metastasis
下载PDF
导出
摘要 目的:研究血浆外泌体来源microRNA(miRNA),作为前列腺癌骨转移的潜在标志物。方法:选取3例初诊为前列腺癌骨转移患者和3例局限性前列腺癌患者,收集患者外周静脉血10 mL,使用超速离心法及透射电子显微镜对血浆外泌体提取和鉴定。应用高通量测序分析血浆外泌体miRNA的差异表达谱。通过基因数据库GEO和已发表文章对差异miRNA筛选,选取测序结果中差异表达miRNAs,对7例局限性前列腺癌患者和10例前列腺癌骨转移患者的血浆外泌体进行qRT-PCR验证,同时结合GEO数据库样本进行验证。结果:高通量测序结果显示,从患者外周血浆外泌体中平均检测到740种miRNAs,通过R软件计算差异miRNA,得出61种差异miRNA;与对照组相比,hsa-miR-885-5p、hsa-miR-1255a、hsa-miR-122-5p、hsa-miR-141-3p、hsa-miR-423-5p、hsa-miR-1224-5p等在骨转移组中差异表达,通过靶基因功能及数据库表达选取miRNA进行PCR验证,发现hsa-miR-423-5p表达差异具有统计学意义(P=0.033)。通过数据库对60例局限性前列腺癌患者和40例骨转移患者统计发现,hsa-miR-423-5p在前列腺癌骨转移中显著下调(P=0.001<0.05)。结论:血浆外泌体来源miR-423-5p在前列腺癌骨转移中显著下调,有望成为前列腺癌骨转移患者中新的标志物。 Objective:To study microRNA(miRNA)derived from plasma exosomes as a potential marker for bone metastasis of prostate cancer.Methods:We select three initially diagnosed patients with bone metastases from prostate cancer and three patients with primary prostate cancer,then collected 10 mL of peripheral venous blood from the patients and extract and identify exosomes by ultracentrifugation and transmission electron microscopy.High-throughput sequencing was used to analyze the differential expression profile of plasma exosome miRNA.We screened differential miRNAs through the genetic database GEO and published articles and selected differentially expressed miRNAs in the sequencing results.The plasma exosomes from 7 patients with primary prostate cancer and 10 patients with prostate cancer bone metastasis were verified by qRT-PCR,and also verified by combining with the GEO database samples.Results:High-throughput sequencing results show that an average of 740 miRNAs were detected from the patient's peripheral plasma exosomes,and differential miRNAs were calculated by R software to obtain 61 differential miRNAs.Compared with the control group,hsa-miR-885-5p,hsa-miR-1255a,hsa-miR-122-5p,hsa-miR-141-3p,hsa-miR-423-5p,hsa-miR-1224-5p and so on were differentially expressed in the bone metastasis group.The miRNA is selected by target gene function and database expression for PCR verification.It is found that the difference in hsa-miR-423-5p expression is statistically significant(P=0.033).According to the statistics of 60 patients with primary prostate cancer and 40 patients with bone metastasis through the database,hsa-miR-423-5p is significantly down-regulated in prostate cancer bone metastasis(P=0.001<0.05).Conclusion:The plasma exosome-derived miR-423-5p is significantly down-regulated in prostate cancer bone metastasis,and is expected to become a new marker in patients with prostate cancer bone metastasis.
作者 姚凯 唐流彪 刘帅 柳长坤 黄天宝 周广臣 YAO Kai;TANG Liubiao;LIU Shuai;LIU Changkun;HUANG Tianbao;ZHOU Guangchen(Clinical Medical College of Yangzhou University,Jiangsu Yangzhou 225000,China.)
出处 《现代肿瘤医学》 CAS 北大核心 2021年第14期2484-2490,共7页 Journal of Modern Oncology
基金 江苏省卫生计生委面上项目(编号:H2017060)。
关键词 前列腺癌骨转移 血浆外泌体miRNA 非入侵标志物 prostate cancer bone metastasis plasma exosome miRNA non-invasive marker
  • 相关文献

同被引文献32

引证文献5

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部